News

FDA and European regulators continue seeking Tavneos withdrawal as Amgen contests the proposed market action.

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The FDA, through a new approval, gave Viridian's drug a label that some on Wall Street believe makes it well-positioned to compete against Tepezza in the thyroid eye disease market.

If you are wondering whether Amgen stock still offers value at current levels, this article walks through what the numbers are actually saying about the price you see on screen. Amgen shares last closed at US$360.55, with returns of 3.9% over the past week, 7.1% over the past month, 10.0% year to date, 27.8% over one year, 75.7% over three years, and 73.2% over five years. This gives investors plenty of price history to weigh against today’s valuation. Recent attention on Amgen has been...

This pharma giant's recent run is grabbing headlines, but its long-term behavior tells a more interesting story about portfolio risk.

Jefferies initiated coverage of Quantinuum stock with a buy rating, touting the company's broad hardware and software platform.

The deal adds navtemadlin—a drug candidate for a rare blood cancer in late-stage clinical trials—to Ipsen’s oncology pipeline.

With just 30 components, the Dow's exclusivity is built on industry leadership, which SpaceX has in spades.

The committee is recommending that no new patients start treatment with Tavneos and that existing patients be switched to suitable alternatives.

The European Medicines Agency said Friday that its Committee for Medicinal Products for Human Use (C

Amgen Inc. (NASDAQ:AMGN) ranks among the best set-it-and-forget-it stocks to buy right now. On June 12, Piper Sandler reaffirmed its Overweight rating and $427 price target for Amgen Inc. (NASDAQ:AMGN). The firm published a detailed review of the Sjogren’s syndrome therapeutic development environment in advance of Amgen’s CD40 ligand-directed fusion protein dazodalibep’s Phase III conclusion […]

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advancements have benefited from elevated demand, which has supported the industry’s returns lately - over the past six months, healthcare stocks have gained 7.6%, nearly mirroring the S&P 500.

7.50am: 3i reveals slower growth for Action 3i Group said its largest portfolio company, Action, remains on track for a good second quarter despite like-for-like sales growth slowing. Ahead of its annual general meeting on Thursday, the FTSE 100-listed private equity investor said European...

In the most recent trading session, Amgen (AMGN) closed at $351.93, indicating a +1.42% shift from the previous trading day.

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Amgen Inc. (NASDAQ:AMGN) is one of the best weight loss drugs on this list. TheFly reported on June 16 that Mizuho analyst Salim Syed increased the price target for AMGN to $303 from $295 while maintaining a Neutral rating on […]

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.

The iShares Nasdaq Biotechnology ETF (IBB) is trading just 1.47% below its 52-week high, signaling a potential multi-year sector breakout.

AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.

They look well-positioned to grab a slice of the fast-growing anti-obesity market.

In June 2026, a Delaware jury ruled that Amgen and its subsidiary Teneobio willfully infringed Harbour BioMed’s Grosveld patent, awarding Harbour US$20,203,704 in damages with the option to seek a tripling of that amount. The verdict, in one of the most closely watched antibody technology patent disputes, highlights legal and financial exposure around Amgen’s antibody discovery platforms and broader IP posture. We’ll now examine how this willful infringement verdict and potential higher...

Yahoo Finance Senior Reporter Brooke DiPalma joins Josh Lipton in highlighting the day's biggest stories and stock moves, including AbbVie's (ABBV) $10.9 billion acquisition of Apogee Therapeutics (APGE) and Coca-Cola's (KO) latest legal showdown with the IRS in US appeals court.

US futures were pointing higher at the start of the week as investors return from the Juneteenth holiday weekend, with technology stocks expected to lead gains despite lingering uncertainty over the Middle East and the prospect of further Federal Reserve tightening. Dow Jones futures were up...

Stock Market Today: The Dow Jones index wavered Monday amid U.S.-Iran peace talks. SpaceX stock dived in premarket trading.

Amgen posts strong profits and cash flow, while NovoCure pursues growth with a direct-to-patient cancer therapy model and leaner balance sheet.

Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

While investors fixate on the pipeline, a powerful and accelerating profit stream from its Sanofi collaboration is quietly reshaping the company's financial core.

The market is focused on Amgen's legacy drugs, but one number shows a new, faster-growing core business is already taking over.

Amgen's (AMGN) well diversified business with no specific product driving over 10% of the top-line,

The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.

Management raised the bar, the stock rocketed higher, and now everyone is wondering if this is the new normal or just a sugar high.